XFOR
X4 Pharmaceuticals, Inc
Key Financials
Operating Income
$-86883000
↓ 138.7%
Net Income
$-79199000
↓ 111.5%
Revenue
$6.5M
↑ 150.0%
EPS (Diluted)
$-1.87
↓ 884.2%
Total Assets
$290.5M
↑ 98.3%
Total Liabilities
$104.2M
↓ 16.2%
Cash & Equivalents
$217.0M
↑ 289.7%
Long-term Debt
$75.0M
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/1/2026 | View on SEC |
| 4 | 7/1/2026 | View on SEC |
| 3 | 7/1/2026 | View on SEC |
| 8-K | 7/1/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| EFFECT | 5/14/2026 | View on SEC |
| 8-K/A | 5/13/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 144 | 5/12/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | XFOR |
| Company Name | X4 Pharmaceuticals, Inc |
| CIK | 1501697 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-529-8300 |